An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center, New York

HemOnCare, P.C., Brooklyn

SUNY Upstate Medical University, Syracuse

Penn State Hershey Medical Center, Hershey

Frederick Memorial Hospital, Frederick

Duke University Medical Center, Durham

Palmetto Health, Columbia

Holy Cross Hospital, Fort Lauderdale

Boston Baskin Cancer Group, Memphis

The Boston Baskin Cancer Group, Memphis

The West Clinic, Memphis

Hematology Oncology Consultants, Inc., Columbus

Ireland Cancer Center, Cleveland

University Hospitals of Cleveland, Cleveland

Southfield Oncology Institute, Inc., Southfield

Josephine Ford Cancer Center, Detroit

Spectrum Health, Grand Rapids

Medical College of Wisconsin-FMLH East Neoplastic Diseases and Related Disorders, Milwaukee

St. Louis Center for Clinical Research, St Louis

University of Arkansas for Medical Sciences, Little Rock

Highlands Oncology Group, Springdale

Center for Oncology Research & Treatment, Dallas

Baylor College of Medicine, Houston

Cancer Specialists of South Texas, PA, Corpus Christi

New Mexico Cancer Care Associates, Santa Fe

Nevada Cancer Center, Las Vegas

San Diego Cancer Research Institute, Vista

Bay Area Cancer Research Group, Concord

California Cancer Care, Inc., Greenbrae

Institute of Cancer Therapies, Los Angeles

Anschutz Cancer Pavilion at the University of Colorado Cancer Center, Aurora

Yale University, New Haven

Rush Cancer Institute, Chicago

University of Kentucky Medical Center, Lexington

Louisiana State University, New Orleans

Dana-Farber/Harvard Cancer Center, Boston

Dartmouth Hitchcock Medical Center, Lebanon

Montefiore Medical Center, The Bronx